TEST BANK |
Calculating |Drug |Dosages: |A |Patient-Safe |Approach |to |Nursing |and |Math |by |Castillo
2nd |Edition
,Table |of |Contents:
I. |Safety |in |Medication |Administration
Chapter |1. |Safety |in |Medication |Administration
Chapter |2. |The |Drug |Label
II. |Systems |of |Measurement
Chapter |3. |The |Metric |System
Chapter |4. |The |Household |System
III. |Methods |of |Calculation
Chapter |5. |Linear |Ratio |and |Proportion
Chapter |6. |Fractional |Ratio |and |Proportion
Chapter |7. |Dimensional |Analysis
Chapter |8. |Formula |Method
IV. |Administration |of |Medications
Chapter |9. |Calculating |Oral |Medication |Doses
Chapter |10. |Syringes |and |Needles
Chapter |11. |Calculating |Parenteral |Medication |Dosages
Chapter |12. |Preparing |Powdered |Parenteral |Medications
Chapter |13. |Administration |of |Insulin
V. |IV |Therapy |and |Administration |of |Intravenous |Medications
Chapter |14. |Intravenous |Infusion |and |Infusion |Rates
Chapter |15. |Calculating |Infusion |and |Completion |Time
Chapter |16. |Administering |IV |Push |Medications
VI. |Verifying |Safe |Dose |and |Critical |Care |Calculations
Chapter |17. |Verifying |Safe |Dose
Chapter |18. |Titration |of |Intravenous |Medications
VII. |Intake |and |Output
Chapter |19. |Calculating |Intake |and |Output
Chapter |20. |Calculating |Parenteral |Intake
VIII. |Dosages |for |Pediatric |and |Older |Adult |Populations
Chapter |21. |Considerations |for |the |Pediatric |Patient
Chapter |22. |Considerations |for |the |Older |Adult
,Chapter |1: |Safety |in |Medication |Administration
Castillo: |Calculating |Drug |Dosages: |A |Patient-Safe |Approach |to |Nursing |and |Math |2nd |Edition
MULTIPLE |CHOICE
1. The |following |medication |order |is |in |the |patient’s |medication |administration |record |(MAR):
methylPREDnisolone |40 |mg |PO |daily |at |0900.
After |reading |the |order, |the |nurse |correctly |determines:
A “PO” |is |an |inappropriate |abbreviation.
B the |medication |order |is |written |correctly.
C 40 |mg |should |be |written |as |40mg.
D tall |man |lettering |indicates |that |the |drug |is |a |narcotic.
ANS: |B
Feedback
The |medication |order |has |all |the |required |components |(drug |name, |dose, |route, |and
|frequency |of |administration) |for |a |drug |order. |“PO” |is |an |appropriate |abbreviation;
|40 |mg |is |written |correctly |with |a |space |between |the |dose |and |the |unit |of
measurement. |Tall |man |lettering |is |used |to |distinguish |the |drug |from |another |drug
|with |a |similar |name.
2. Which |of |the |following |accurately |describes |the |“Boxed |Warning” |found |on |a |drug |label?
A It |is |primarily |is |used |to |identify |the |safe |dose |for |the |patient.
B It |is |commonly |found |on |all |drug |labels.
C It |identifies |serious |potential |risks |and |side |effects |related |to |drug |use.
D It |protects |the |patient |by |providing |information |to |decrease |side |effects.
ANS: |C
Feedback
A |drug |label |with |a |boxed |warning |provides |information |to |healthcare |professionals
|and |patients |regarding |the |serious |risks |and |side |effects |related |to |the |drug. |The
|Boxed |Warning |is |not |the |primary |source |for |identifying |the |patient’s |drug |dosage.
The |warning |is |found |on |specific |prescription |medications |and |does |not |provide
|information |to |reduce |or |decrease |side |effects.
3. When |practicing |safety |in |the |administration |of |medication, |for |which |of |the |following
|medication |orders |should |a |nurse |seek |clarification |before |the |administration |of |the
|medication?
1
, A Regular |insulin |5 |u |subcut |now.
B Enoxaparin |80 |mg |subcut |every |12 |hours.
C Benadryl |50 |mg |PO |PRN |every |6 |hr |for |itching.
D Ondansetron |4 |mg |IVP |stat.
ANS: |A
Feedback
The |“u” |should |never |be |used |in |a |medication |order; |rather, |for |safety, |the |word
“units” |should |be |spelled |out. |The |other |answer |options |contain |the |required
|components |needed |to |safely |carry |out |the |medication |order.
4. A |nurse |is |reviewing |a |drug |label |with |a |drug |name |written |with |tall |man |lettering. |Which
|statements |shows |the |nurse |has |a |correct |understanding |of |tall |man |lettering |on |a |drug |label?
A “The |tall |man |lettering |means |this |is |a |high |alert |drug.”
B “The |tall |man |lettering |helps |me |distinguish |this |drug |with |other |drugs |that
have |similar |names.”
C “The |tall |man |lettering |means |that |this |drug |must |have |a |Boxed |Warning.”
D “The |tall |man |lettering |helps |me |quickly |identify |that |this |drug |is |an |injectable
|drug.”
ANS: |B
Feedback
Tall |man |lettering |highlights |a |portion |of |the |drug |name |to |help |distinguish |from
similar |drug |names. |It |is |not |used |to |identify|high |alert |drugs, |highlight |a |boxed |warning,
|or |identify |injectable |drugs.
5. The |following |medication |orders |are |found |in |the |patient’s |MAR:
Metformin |HCl |500 |mg |PO |daily |at |0900. |Hydrochlorothiazide
|25 |mg |PO |every |12 |hr |at |0900 |and |2100. |Digoxin |.25 |mg |PO
|daily |at |0900.
In |reading |the |medication |orders |for |the |0700–1500 |shift, |the |nurse |determines |that |which |of
|the |following |is |the |priority |nursing |intervention?
A Clarify |the |metformin |HCl |order.
B Clarify |the |hydrochlorothiazide |order.
C Clarify |the |digoxin |order.
D Prepare |to |administer |the |0900 |medications.
ANS: |C
2
Calculating |Drug |Dosages: |A |Patient-Safe |Approach |to |Nursing |and |Math |by |Castillo
2nd |Edition
,Table |of |Contents:
I. |Safety |in |Medication |Administration
Chapter |1. |Safety |in |Medication |Administration
Chapter |2. |The |Drug |Label
II. |Systems |of |Measurement
Chapter |3. |The |Metric |System
Chapter |4. |The |Household |System
III. |Methods |of |Calculation
Chapter |5. |Linear |Ratio |and |Proportion
Chapter |6. |Fractional |Ratio |and |Proportion
Chapter |7. |Dimensional |Analysis
Chapter |8. |Formula |Method
IV. |Administration |of |Medications
Chapter |9. |Calculating |Oral |Medication |Doses
Chapter |10. |Syringes |and |Needles
Chapter |11. |Calculating |Parenteral |Medication |Dosages
Chapter |12. |Preparing |Powdered |Parenteral |Medications
Chapter |13. |Administration |of |Insulin
V. |IV |Therapy |and |Administration |of |Intravenous |Medications
Chapter |14. |Intravenous |Infusion |and |Infusion |Rates
Chapter |15. |Calculating |Infusion |and |Completion |Time
Chapter |16. |Administering |IV |Push |Medications
VI. |Verifying |Safe |Dose |and |Critical |Care |Calculations
Chapter |17. |Verifying |Safe |Dose
Chapter |18. |Titration |of |Intravenous |Medications
VII. |Intake |and |Output
Chapter |19. |Calculating |Intake |and |Output
Chapter |20. |Calculating |Parenteral |Intake
VIII. |Dosages |for |Pediatric |and |Older |Adult |Populations
Chapter |21. |Considerations |for |the |Pediatric |Patient
Chapter |22. |Considerations |for |the |Older |Adult
,Chapter |1: |Safety |in |Medication |Administration
Castillo: |Calculating |Drug |Dosages: |A |Patient-Safe |Approach |to |Nursing |and |Math |2nd |Edition
MULTIPLE |CHOICE
1. The |following |medication |order |is |in |the |patient’s |medication |administration |record |(MAR):
methylPREDnisolone |40 |mg |PO |daily |at |0900.
After |reading |the |order, |the |nurse |correctly |determines:
A “PO” |is |an |inappropriate |abbreviation.
B the |medication |order |is |written |correctly.
C 40 |mg |should |be |written |as |40mg.
D tall |man |lettering |indicates |that |the |drug |is |a |narcotic.
ANS: |B
Feedback
The |medication |order |has |all |the |required |components |(drug |name, |dose, |route, |and
|frequency |of |administration) |for |a |drug |order. |“PO” |is |an |appropriate |abbreviation;
|40 |mg |is |written |correctly |with |a |space |between |the |dose |and |the |unit |of
measurement. |Tall |man |lettering |is |used |to |distinguish |the |drug |from |another |drug
|with |a |similar |name.
2. Which |of |the |following |accurately |describes |the |“Boxed |Warning” |found |on |a |drug |label?
A It |is |primarily |is |used |to |identify |the |safe |dose |for |the |patient.
B It |is |commonly |found |on |all |drug |labels.
C It |identifies |serious |potential |risks |and |side |effects |related |to |drug |use.
D It |protects |the |patient |by |providing |information |to |decrease |side |effects.
ANS: |C
Feedback
A |drug |label |with |a |boxed |warning |provides |information |to |healthcare |professionals
|and |patients |regarding |the |serious |risks |and |side |effects |related |to |the |drug. |The
|Boxed |Warning |is |not |the |primary |source |for |identifying |the |patient’s |drug |dosage.
The |warning |is |found |on |specific |prescription |medications |and |does |not |provide
|information |to |reduce |or |decrease |side |effects.
3. When |practicing |safety |in |the |administration |of |medication, |for |which |of |the |following
|medication |orders |should |a |nurse |seek |clarification |before |the |administration |of |the
|medication?
1
, A Regular |insulin |5 |u |subcut |now.
B Enoxaparin |80 |mg |subcut |every |12 |hours.
C Benadryl |50 |mg |PO |PRN |every |6 |hr |for |itching.
D Ondansetron |4 |mg |IVP |stat.
ANS: |A
Feedback
The |“u” |should |never |be |used |in |a |medication |order; |rather, |for |safety, |the |word
“units” |should |be |spelled |out. |The |other |answer |options |contain |the |required
|components |needed |to |safely |carry |out |the |medication |order.
4. A |nurse |is |reviewing |a |drug |label |with |a |drug |name |written |with |tall |man |lettering. |Which
|statements |shows |the |nurse |has |a |correct |understanding |of |tall |man |lettering |on |a |drug |label?
A “The |tall |man |lettering |means |this |is |a |high |alert |drug.”
B “The |tall |man |lettering |helps |me |distinguish |this |drug |with |other |drugs |that
have |similar |names.”
C “The |tall |man |lettering |means |that |this |drug |must |have |a |Boxed |Warning.”
D “The |tall |man |lettering |helps |me |quickly |identify |that |this |drug |is |an |injectable
|drug.”
ANS: |B
Feedback
Tall |man |lettering |highlights |a |portion |of |the |drug |name |to |help |distinguish |from
similar |drug |names. |It |is |not |used |to |identify|high |alert |drugs, |highlight |a |boxed |warning,
|or |identify |injectable |drugs.
5. The |following |medication |orders |are |found |in |the |patient’s |MAR:
Metformin |HCl |500 |mg |PO |daily |at |0900. |Hydrochlorothiazide
|25 |mg |PO |every |12 |hr |at |0900 |and |2100. |Digoxin |.25 |mg |PO
|daily |at |0900.
In |reading |the |medication |orders |for |the |0700–1500 |shift, |the |nurse |determines |that |which |of
|the |following |is |the |priority |nursing |intervention?
A Clarify |the |metformin |HCl |order.
B Clarify |the |hydrochlorothiazide |order.
C Clarify |the |digoxin |order.
D Prepare |to |administer |the |0900 |medications.
ANS: |C
2
